The article informs that the Recombinant DNA Advisory Committee (RAC) established by the U.S. National Institutes of Health (NIH) in 1974 is looking to set to ease its oversight over gene therapy research by providing a welcome relief to U.S. academics and companies working in the field as of September 2014. Views of Barry Byrne, director of the University of Florida Powell Gene Therapy Center, are also presented on the issue.